- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Elicera Therapeutics AB: Elicera Therapeutics receives notice of allowance for ELC-401 patent in China | 393 | GlobeNewswire (Europe) | Uppsala, Sweden, 5 November 2026 - Elicera Therapeutics AB (publ) today announces that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance for a patent application... ► Artikel lesen | |
| 03.11. | Mitbegründer von Elicera Therapeutics erhält 4 Millionen SEK für CAR-T-Forschung gegen solide Tumoren | 4 | Bionity.com | ||
| 30.10. | Elicera Therapeutics AB: Elicera Therapeutics co-founder receives grant totaling SEK 4 million from the Swedish Research Council for research on CAR-T cells against solid tumors | 179 | GlobeNewswire (Europe) | Uppsala, October 30th, 2026 - Elicera Therapeutics (publ) today announces that the company's co-founder, Dr. Di Yu, has been awarded a grant totaling SEK 4 million from the Swedish Research Council.... ► Artikel lesen | |
| 12.10. | Elicera Therapeutics AB: Elicera Therapeutics completes Phase I part of CARMA study of ELC-301 and reports complete metabolic response in 8 of 12 patients | 306 | GlobeNewswire (Europe) | Uppsala, October 12, 2026 - Elicera Therapeutics AB (publ) today announces that the Phase I part of the CARMA study has been completed. The study is evaluating the safety and preliminary efficacy of... ► Artikel lesen | |
| 02.10. | Elicera Therapeutics to participate in upcoming investor and partnering events | 2 | Cision News | ||
| 17.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Medical Products Agency Approval to Advance CARMA Study into Phase IIa in B-cell Lymphoma | 272 | GlobeNewswire (Europe) | Uppsala, September 17, 2026 - Elicera Therapeutics AB (publ) announced today that the Swedish Medical Products Agency (Läkemedelsverket) has approved a substantial modification to the clinical trial... ► Artikel lesen | |
| 09.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma | 249 | GlobeNewswire (Europe) | Uppsala, September 9, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.09. | Elicera Therapeutics AB: Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors | 245 | GlobeNewswire (Europe) | Uppsala, September 1, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate | 642 | GlobeNewswire (Europe) | Gothenburg, August 28, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026 | 261 | GlobeNewswire (Europe) | Second quarter (January-March 2026)
Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
Loss for the period amounted to SEK -6,261,763 (-2,732,070)
Cash flow from operating activities... ► Artikel lesen | |
| 18.08. | Elicera Therapeutics AB: Elicera Therapeutics appoints Johan Liwing as new CEO | 582 | GlobeNewswire (Europe) | Gothenburg, August 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.08. | ELICERA THERAPEUTICS AB: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 1 | Cision News | ||
| 11.08. | Elicera Therapeutics AB: Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 325 | GlobeNewswire (Europe) | Gothenburg, August 11, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 24.07. | Elicera Therapeutics AB: Elicera Therapeutics consolidates its management in Uppsala - CEO transition begins and recruitment of new CEO has started | 237 | GlobeNewswire (Europe) | Gothenburg, July 24, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 18.06. | Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma | 1 | Cision News | ||
| 03.06. | ELICERA THERAPEUTICS AB: Elicera publishes annual report for 2025 | 1 | Cision News | ||
| 01.06. | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 397 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 565 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 286 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 1.633 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,116 | -0,06 % | EQS-News: Evotec SE gibt Ergebnisse für das 3. Quartal und die ersten neun Monate 2026 bekannt: Wachstum auf Kurs zu den Zielen bis 2030 | EQS-News: Evotec SE
/ Schlagwort(e): 9-Monatszahlen/Quartals-/Zwischenmitteilung
Evotec SE gibt Ergebnisse für das 3. Quartal und die ersten neun Monate 2026 bekannt: Wachstum... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 818,90 | -0,33 % | Regeneron-Aktie: Erneute Aufwärtsbewegung nach Konsolidierung | Nach den jüngsten Quartalsergebnissen erreichte Regeneron ein neues Jahreshoch, bevor eine Konsolidierung einsetzte. Die anschließende Kurserholung hat ein höheres Tief hinterlassen, während das bisherige... ► Artikel lesen | |
| BRAIN BIOTECH | 2,570 | -0,77 % | BRAIN Biotech kooperiert mit Syngenta bei biologischem Pflanzenschutz | ||
| CARDIOL THERAPEUTICS | 0,923 | +0,98 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| CSL | 124,84 | +1,96 % | Buy, hold, sell: CSL, NextDC, PLS shares | ||
| BURCON NUTRASCIENCE | 0,655 | +8,26 % | Burcon NutraScience Corporation: Burcon Announces Fiscal Year 2027 Second Quarter Conference Call and Presentation to be Held on November 16, 2026 | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| MANNKIND | 3,801 | +0,42 % | Cantor Fitzgerald hebt Kursziel für MannKind wegen Tyvaso-Dynamik auf 10 US-Dollar an | ||
| OCULAR THERAPEUTIX | 5,850 | -1,68 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,452 | -1,92 % | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | ||
| ADAPTIMMUNE THERAPEUTICS | 0,025 | -100,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 0,923 | +2,44 % | CODEXIS, INC. - 8-K, Current Report | ||
| CORMEDIX | 4,845 | +1,00 % | Cormedix Q3 2026 Earnings Call Transcript | ||
| TELO GENOMICS | 0,031 | -7,46 % | Telo Genomics Corp.: Telo Genomics Announces $250,000 Term Loan Facility | Non-dilutive secured term loan from BrightArc Capital to fund operating expenses.Vancouver, British Columbia--(Newsfile Corp. - November 6, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 2,435 | -5,98 % | Aligos Therapeutics GAAP EPS of -$2.09 beats by $0.19, revenue of $2.83M misses by $2.71M | ||
| VTV THERAPEUTICS | 18,500 | 0,00 % | vTv Therapeutics GAAP EPS of -$0.94 beats by $0.15 |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,205 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.